替吉奥、替吉奥与顺铂联合治疗进展期胃癌92例疗效对比分析  

Analysis of Gimeracil and Oteracil Porassium Capsules and cisplatin treatment in 92 cases with advanced gastric cancer

作　　者：衣学新[1] 

机构地区：[1]临朐县人民医院血液肿瘤科,山东潍坊262600

出　　处：《现代预防医学》2012年第7期1820-1821,1827,共3页Modern Preventive Medicine

摘　　要：目的对比单用替吉奥胶囊和替吉奥胶囊联合顺铂两种方案治疗晚期胃癌的近期疗效和毒副反应。方法选取晚期胃癌患者92例,随机分为替吉奥组和联合组各46例,两组分别应用替吉奥和替吉奥联合顺铂进行治疗,疗程2个周期,评价两组疗效及毒副反应。结果替吉奥组和联合组总有效率分别为32.61%和54.35%;无进展生存期分别为126d和159d;两组均有良好的耐受性,无预期外严重不良反应,Ⅲ～Ⅳ度不良反应发生率低。结论替吉奥联合顺铂方案对晚期胃癌患者一线治疗有良好的疗效和安全性,有望做为晚期胃癌患者的标准治疗方案之一。OBJECTIVE To compare short-term efficacy and toxicity of the single use of Gimeracil and Oteracil Porassium Capsules and combined use of Gimeracil and Oteracil Porassium Capsules with cisplatin for the treatment of advanced gastric cancer patients.METHODS 92 patients with advanced gastric cancer were randomly divided into Gimeracil and Oteracil Porassium Capsules Group and Gimeracil and Oteracil Porassium Capsules-cisplatin group with 46 in each.2 cycles of treatment were used for both teams.Effect and toxicity were evaluated.RESULTS The effective rate of Gimeracil and Oteracil Porassium Capsules group and combination group was 32.61% and 54.35% respectively;Disease progression-free survival were 126 d and 159 d respectively;two groups had no unexpected serious adverse reactions and had low incidence of Ⅲ-Ⅳ degree adverse reactions.CONCLUSION Gimeracil and Oteracil Porassium Capsules combined with cisplatin for advanced gastric cancer patients had good efficacy and safety,and is one of the standard treatments for advanced gastric cancer patients.

关 键 词：替吉奥 顺铂 联合 进展期胃癌 

分 类 号：R979.1[医药卫生—药品]